← 홈

ADC · HER2

142개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 142개
ADCBiologicSWOG Cancer Research NetworkDM1) and/or trastuzumab der…Phase 3

HER2-targeted Therapy (HER2-targeted Therapy)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 18.75%임상시험 59상태 RECRUITING
ADCBiologicRocheDM1 via butelase-1 with ABD…Phase 3

T-DM1 (Trastuzumab emtansine, Trastuzumab emtansine (T-DM1))

Advanced Breast Cancer; Objective Response Rate · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 69.7%임상시험 59상태 RECRUITING
ADCBiologicJules Bordet InstituteReleasePhase 2

Neratinib (Neratinib)

Breast Cancer; Brain Metastases · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 57.1%임상시험 58상태 RECRUITING
ADCBiologicAssistance Publique - Hôpitaux …Phase 2

Adjuvant Systemic Therapy (Adjuvant Systemic Therapy)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 10%임상시험 57상태 RECRUITING
ADCBiologicRocheDM1 via butelase-1 with ABD…Phase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1)

Bone Metastases; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 69.7%임상시험 57상태 ACTIVE
ADCBiologicRemeGen Co., Ltd.sPhase 2

disitamab vedotin (Disitamab Vedotin, RC48)

Non-Muscle Invasive Bladder Cancer; HER2 · Gastric Cancer/Gastroesophageal Junction

#GastricCancerGastroesophagealJun#ADC#Phase2#인기#항체약물접합체+5
임상시험 56상태 RECRUITING
ADCBiologicSeagen Inc.deruxtecan and tucatinibPhase 1

ONT-380 (Tucatinib, Tucatinib (ONT-380))

HER2 Positive Breast Cancers · HER2

#HER2#ADC#Phase1#인기#항체약물접합체+5
효능 ORR 100%임상시험 54상태 ACTIVE
ADCBiologicQuantumLeap Healthcare Collabor…Phase 2

ABT-888 (ABT-888)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 74.1%임상시험 53상태 RECRUITING
ADCBiologicJiangsu HengRui Medicine Co., L…Phase 2

Famitinib (Famitinib)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
임상시험 53상태 RECRUITING
ADCBiologicFudan UniversityderuxtecanPhase 2

Dalpiciclib (Dalpiciclib)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
임상시험 52상태 RECRUITING
ADCBiologicSWOG Cancer Research Networkderuxtecan (T-DXd) and tyro…Phase 3

Cyclin-Dependent Kinase 4 Inhibitor (Cyclin-Dependent Kinase 4 Inhibitor)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 57.98%임상시험 50상태 RECRUITING
ADCBiologicHoffmann-La RochePhase 2

Entinostat (Entinostat)

Breast Neoplasms · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 22.2%임상시험 50상태 DISCONTINUED
ADCBiologicSWOG Cancer Research NetworkPhase 3

Cyclin-Dependent Kinase 6 Inhibitor (Cyclin-Dependent Kinase 6 Inhibitor)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 24%임상시험 47상태 RECRUITING
ADCBiologicEMD Serono Research & Developme…Phase 3

M7824 (M7824)

Non-small Cell Lung Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 62.5%임상시험 43상태 DISCONTINUED
ADCBiologicNYU Langone Healthderuxtecan (T-DXd) (PFS HR&…Phase 2

Elacestrant (Elacestrant)

ER Positive, HER2 Positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
임상시험 38상태 RECRUITING
ADCBiologicBeijing Biostar Pharmaceuticals…Phase 2

Utidelone (Utidelone)

Non-small Cell Lung Cancer Patients with Brain Metastases · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 36상태 RECRUITING
ADCBiologicstaleGBG Forschungs GmbHPhase 2

Inavolisib (Inavolisib)

HER2-positive Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 11.5%임상시험 31상태 RECRUITING
ADCBiologicstaleBristol-Myers SquibbPhase 2

Taxane Chemotherapy (Taxane Chemotherapy)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 81.1%임상시험 31상태 RECRUITING
ADCBiologicstaleSWOG Cancer Research NetworkPhase 3

Taxane Compound (Taxane Compound)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 69.3%임상시험 31상태 RECRUITING
ADCBiologicstaleChipscreen Biosciences, Ltd.Phase 3

taxane drug (taxane drug)

HER2-positive Metastatic Breast Cancer; First-line Treatment · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 81.1%임상시험 31상태 RECRUITING

2 / 8 페이지

← 이전다음 →